NCT05127473 - A Research Study of How a New Medicine NNC0365-3769 (Mim8) Works in the Body of Healthy People | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 14, 2021

Primary Completion Date

May 14, 2022

Study Completion Date

May 14, 2022

Conditions

Healthy Volunteers - Haemophilia A

Interventions

DRUG

Mim8 B, 10 mg/mL

All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.

DRUG

Mim8 B, 100 mg/mL

All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.

DRUG

Mim8 B, placebo

Placebo will be used to dilute the IMP to different Mim8 concentrations

Trial Locations (2)

41460

Novo Nordisk Investigational Site, Neuss

55116

Novo Nordisk Investigational Site, Mainz